专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

41. 发明公开

EP1025444A1 DETERMINATION OF CELLULAR GROWTH ABNORMALITY 有权
标题翻译：细胞生长异常的测定
公开(公告)号：EP1025444A1
公开(公告)日：2000-08-09
申请号：EP98949123.8
申请日：1998-10-21
申请人： CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED
发明人： LASKEY, Ronald, Alfred , WILLIAMS, Gareth, Haydn , COLEMAN, Nicholas
IPC分类号： G01N33/574
CPC分类号： G01N33/57411 , G01N33/57496
摘要： Determination of cellular growth abnormality, particularly cancerous abnormality, by detection of target polypeptides or encoding mRNA, where the target polypeptides are members of the preinitiation complex of DNA replication in tissue, cells or fluid. Target polypeptides include CDC6, MCM2, MCM3, MCM4, MCM5, MCM6 and MCM7. Test samples include tissue of the cervix (both biopsy and smear samples), breast, colon, lung, bladder, skin, larynx, oesophagus, bronchus, lymph nodes and urinary tract (both biopsy and cytology smear samples), in determination of cancerous and pre-cancerous cellular growth abnormality, and cells spun from urine, blood and serum, in determination of haematological malignancies and evidence of metastatic sarcoma and carcinoma.
摘要翻译：通过检测目标多肽或编码mRNA来确定细胞生长异常，特别是癌性异常，其中目标多肽是组织，细胞或液体中DNA复制的预起始复合物的成员。靶多肽包括CDC6，MCM2，MCM3，MCM4，MCM5，MCM6和MCM7。测试样本包括宫颈组织（活检和涂片样本），乳房，结肠，肺，膀胱，皮肤，喉，食道，支气管，淋巴结和尿道（活检和细胞学涂片样本）癌前细胞生长异常，以及尿液，血液和血清中的细胞，测定血液恶性肿瘤以及转移性肉瘤和癌症的证据。

42. 发明公开

EP0864001A1 GLOBAL AMPLIFICATION OF NUCLEIC ACIDS 失效
标题翻译： UNIVERSAL扩增核酸
公开(公告)号：EP0864001A1
公开(公告)日：1998-09-16
申请号：EP97937733.0
申请日：1997-08-29
申请人： CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED
发明人： HAMPSON, Ian, Noel , HAMPSON, Lynne
IPC分类号： C12N15 , C12Q1
CPC分类号： C12N15/1096 , C12Q1/686 , C12Q2600/158 , C12Q2565/518 , C12Q2525/179
摘要： Nucleic acid starting material composed of a collection of single stranded nucleic acid molecules is anchored and processed by a directional random priming method to produce a mixture of shorter random size DNA molecules well-suited for achieving substantially uniform global PCR amplification. The processing and global amplification method disclosed is especially useful in conjunction with subtractive hybridization procedures applied, for example, to the study of differential gene expression.

43. 发明授权

EP0633029B1 Further improvements relating to drug delivery systems 失效
标题翻译：增强输送系统的药物
公开(公告)号：EP0633029B1
公开(公告)日：1997-11-26
申请号：EP94113490.0
申请日：1989-04-21
申请人： CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED , ZENECA LIMITED
发明人： Bagshawe, Kenneth D., CRC Lab. Dpt. , Rogers, Gordon T., CRC Lab. Dpt. of Medical Oncol. , Sharma, Surinder, CRC Lab. Dpt. of Medical Oncol.
IPC分类号： A61K47/00
CPC分类号： B82Y5/00 , A61K38/00 , A61K47/6893 , A61K47/6898 , A61K47/6899 , C07K16/26 , C07K16/30 , C07K16/3007 , C07K16/40

44. 发明公开

EP0788554A1 SEQUENCE ANALYSIS OF SACCHARIDE MATERIAL 失效
标题翻译：糖的序列分析
公开(公告)号：EP0788554A1
公开(公告)日：1997-08-13
申请号：EP95935507.0
申请日：1995-10-30
申请人： CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED
发明人： GALLAGHER, John, Thomas , TURNBULL, Jeremy, Ewan , HOPWOOD, John, Joseph
IPC分类号： G01N33 , C12Q1
CPC分类号： C12Q1/34 , G01N2333/924 , G01N2400/40
摘要： In a method of analysing saccharide material such as glycosaminoglycans (GAG's) to determine the sequence of monosaccharide units in oligosaccharide chains thereof, the saccharide chains are end referenced, e.g. by labelling or tagging at their reducing ends, and the saccharide material is subjected to a controlled partial depolymerisation using a selective scission reagent, for example low pH nitrous acid, which cleaves internal glycosidic linkages in accordance with a known linkage specificity so as to produce a mixed set of saccharide chain fragments having different lengths ranging throughout the full spectrum of possible lengths for the particular glycosidic linkage specificity of the selective scission reagent employed. Samples of the mixed set of saccharide chain fragments are then treated with selected exoenzymes including exoglycosidases that cleave only particular glycosidic linkages at the non-reducing end of saccharide chains and exosulphatases that selectively remove sulphate groups from monosaccharide residues at the non-reducing end of saccharide chains. These exoenzymes are applied to the samples either singly or in combination in accordance with a predetermined strategy. The treated samples are then analysed, conveniently by polyacrylamide gel electrophoresis (PAGE) to detect the chain fragments present which have a reducing end derived from the reducing end of the corresponding chain in the original saccharide material. Using PAGE, preferably gradient PAGE, the different samples are run in parallel tracks of the gel and a migration banding pattern is obtained that provides information which enables the monosaccharide sequence in the original saccharide material to be deduced.

45. 发明公开

EP0737319A1 FOCAL NEUROGRAPHIC MAGNETIC RESONANCE IMAGING SYSTEM 失效
标题翻译：成像系统磁共振FOKAL-CHART神经的
公开(公告)号：EP0737319A1
公开(公告)日：1996-10-16
申请号：EP94919373.0
申请日：1994-06-06
申请人： University of Washington , ST. GEORGE'S HOSPITAL MEDICAL SCHOOL , THE WELLCOME TRUST , CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED
发明人： FILLER, Aaron, G., Atkinson Molrey's Hospital , HOWE, Franklyn, A.
IPC分类号： A61B5 , G01R33 , H01F5
CPC分类号： G01R33/34084 , G01R33/34 , G01R33/3806 , G01R33/385 , G01R33/56341
摘要： A focal magnetic resonance imaging system (20) for generating images of neural structures such as nerves. The system (20) includes a control and analysis system (22), a polarizing system (24), and splint-coil assembly (26). The splint-coil assembly (26) includes a splint (28) and various magnetic and electromagnetic coils (32, 40, 42) incorporated within the splint (28). The splint (28) conforms snugly to a patient's body part, e.g., limb, so that the coils (32, 40, 42) are fixed with respect to the patient's body part. The splint-coil assembly (26) can be positioned independently of a main field generated by the polarizing system (24), and a stabilization apparatus (156) is included for adjustably securing the position of the splint-coil assembly (26) during imaging. A focal magnet assembly (60) that can serve as the polarizing system (24) is also provided. Further provided is a method of operating the control and analysis system (22) to consistently generate images depicting the fascicular structure of nerves (100) by ensuring that image gradients (108) are oriented orthogonal to the nerves (100).

46. 发明公开

EP0702683A1 06-SUBSTITUTED GUANINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND THEIR USE IN TREATING TUMOUR CELLS 失效
标题翻译： O6 - 取代GUANINEDERIVATE，进程中为其及其用于肿瘤细胞的治疗
公开(公告)号：EP0702683A1
公开(公告)日：1996-03-27
申请号：EP94916373.0
申请日：1994-06-08
申请人： CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED
发明人： McMURRY, Thomas Brian Hamilton , McELHINNEY, Robert Stanley , McCORMICK, Joan Elizabeth , ELDER, Rhoderick, Hugh c/o Christie Hospital , Kelly, Jane Christie Hospital
IPC分类号： C07D487 , A61K31 , A61P35 , C07D473 , C07H19
CPC分类号： C07H19/16 , C07D473/18
摘要： O^_6-hetarylalkyl- or naphthylalkylguanine derivatives of formula (I) wherein Y is H, ribosyl, deoxyribosyl, or R'XCHR'', wherein X is O or S, R'' and R''' are alkyl, or substituted derivatives thereof; R' is H, or alkyl or hydroxyalkyl; R is (i) a cyclic group having at least one 5- or 6-membered heterocyclic ring, optionally with a carbocyclic or heterocyclic ring fused thereto, the or each heterocyclic ring having at least one hereto atom chosen from O, N or S, or a substituted derivative thereof; or (ii) naphthyl or a substituted derivative thereof; and pharmaceutically acceptable salts thereof, exhibit the ability to deplete O^_6-alkylguanine-DNA alkyltransferase (ATase) activity. A process for preparation of the compounds is described. The compounds have utility in combination with alkylating agents in the chemotherapeutic treatment of tumour cells.

47. 发明授权

EP0408546B1 IMPROVEMENTS RELATING TO DRUG DELIVERY SYSTEMS 失效
标题翻译：分布药物系统。
公开(公告)号：EP0408546B1
公开(公告)日：1994-04-27
申请号：EP88902177.0
申请日：1988-03-09
申请人： CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED , ZENECA LIMITED
发明人： BAGSHAWE, Kenneth D., Charing Cross Hospital , JARMAN, Michael , SPRINGER, Caroline Joy, Charing Cross Hospital
IPC分类号： A61K39/395 , A61K45/05
CPC分类号： B82Y5/00 , A61K39/395 , A61K45/05 , A61K47/6899 , A61K2300/00
摘要： A two component system designed for use in association with one another comprises (i) a first component that is an antibody fragment capable of binding with a tumour associated antigen, the antibody fragment being bound to an enzyme capable of converting a cytotoxic pro-drug into a cytotoxic drug, (ii) a second component that is a cytotoxic pro-drug convertible under the influence of the enzyme to the cytotoxic drug. This system can be used to control neoplastic cell growth and is designed to improve localisation of the cytotoxic drug. The system utilises benzoic acid nitrogen mustard glutamides convertible to the nitrogen mustard under the influence of carboxypeptidases.

48. 发明授权

EP0437487B1 TARGETTING AGENTS 失效
标题翻译：目标代理商
公开(公告)号：EP0437487B1
公开(公告)日：1994-03-09
申请号：EP89911284.1
申请日：1989-10-04
申请人： CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED
发明人： PAGE-THOMAS, David, Peter , BARD, David, Roy , KNIGHT, Clive, Graham
IPC分类号： A61K47/48 , A61K37/32 , C07K99/10 , C07K7/24
CPC分类号： A61K47/62
摘要： A product of formula (I): R-(M)n, wherein n is greater than 1, each M is an N-terminus-linked polypeptide selected from alpha-melanocyte stimulating hormone (MSH) and derivatives and analogues thereof and R is a targetted moiety optionally bonded to the groups M by a linking group.
摘要翻译：式（I）的产物：R-（M）n，其中n大于1，每个M是选自α-黑素细胞刺激激素（MSH）及其衍生物和类似物的N-末端连接的多肽，R是任选通过连接基团与基团M键合的靶向部分。

49. 发明授权

EP0206802B1 Substituted quinoline derivatives 失效
标题翻译：取代的喹啉衍生物
公开(公告)号：EP0206802B1
公开(公告)日：1993-09-01
申请号：EP86304820.3
申请日：1986-06-23
申请人： CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED
发明人： Atwell, Graham John , Denny, William Alexander , Rewcastle, Gordon William ,
IPC分类号： C07D215/48 , C07D401/04 , C07D241/44 , C07D215/60 , C07D241/52 , A61K31/47 , A61K31/495
CPC分类号： C07D401/04 , C07D215/48 , C07D241/44

50. 发明公开

EP0540263A1 Bacterial nitroreductase for the reduction of CB 1954 and analogues thereof to a cytotoxic form 失效
标题翻译： Bakteriennitroreduktase减少CB1954和类似物于细胞毒性公式。
公开(公告)号：EP0540263A1
公开(公告)日：1993-05-05
申请号：EP92309740.6
申请日：1992-10-23
申请人： CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED
发明人： Anlezark, Gillian PHLS Ctr. for Appl. Microbiology , Melton, Roger, PHLS Ctr for Applied Microbiology , Sherwood, Roger, PHLS Ctr for Applied Microbiology , Connors, Thomas, MRC Toxicology Unit , Friedlos, Frank Institute of Cancer Research , Jarman, Michael Institute of Cancer Research , Knox, Richard Institute of Cancer Research , Mauger, Anthony Institute of Cancer Research , SPRINGER, Caroline Joy, The Inst.of CancerResearch
IPC分类号： C12N15/53 , C12N9/02 , C12P21/08 , C12P7/10 , C07K7/06 , C07D487/14 , C07D203/14 , C07C271/18 , C07C219/34 , C07H15/252 , C07H19/048 , A61K31/13 , A61K31/06 , A61K31/395 , A61K31/70 , A61K31/41 , A61K37/02
CPC分类号： C07D203/14 , A61K38/00 , C07C219/34 , C07C271/18 , C07D487/14 , C07H15/252 , C07H19/048 , C07K7/06 , C12N9/0036 , C12P17/10 , C12Y101/01284 , Y02E50/16
摘要： The invention provides a nitroreductase, obtainable from a bacterium having the following characteristics as exemplified by examples isolated from Escherichia coli B and Bacillus amyloliquifaciens :

1. It is a flavoprotein having a molecular weight in the range 20-60 Kilodaltons;
2. It requires either NADH or NAD(P)H or analogues thereof as a cofactor;
3. It has a Km for NADH or NAD(P)H in the range 1-100µM; and
4. It is capable of reducing either or both nitro groups of CB 1954 and analogues thereof to a cytotoxic form e.g. the hydroxylamine.

The sequence of one such nitroreductase is shown in Seq. ID No.1. The nitroreductase may be conjugated to a tumor targeting agent such as a monoclonal antibody and used to convert prodrugs into active antitumour agents. Such prodrugs and drugs are also provided.
摘要翻译：本发明提供了硝基还原酶，由具有以下特征的细菌获得的阿通过从大肠杆菌B和芽胞杆菌分离amyloliquifaciens的例子所例示：1。这是在范围具有分子量20-60千道尔顿的黄素蛋白; 2.它需要NADH或NAD（P）H或作为辅因子及其类似物; 3.它具有的Km NADH或NAD（P）在范围H 1〜100 <0>米; 和4.能够减少任一者或CB 1954的两个硝基和其类似物的细胞毒性形式的E.G. 羟胺。一个寻求硝基还原酶的序列示于序列。 ID号。硝基还原酶可以缀合到肿瘤靶向剂：如单克隆抗体，并用于前药转化为活性的抗肿瘤剂。因此，提供了搜索的前体药物和药物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式